11:29 AM EDT, 06/24/2025 (MT Newswires) -- Cosmos Health ( COSM ) said on Tuesday it will expand beyond its existing European footprint and begin production in the US via a strategic agreement with DolCas Biotech, a New Jersey-based manufacturer of nutraceutical ingredients.

Cosmos, which produces several proprietary pharmaceutical and nutraceutical brands in addition to making food supplements, cosmetics, biocides, and medical devices sold within the European Union, said the move will reduce the company's potential exposure to US tariffs on imported goods and help mitigate cross-border logistical difficulties.

Financial terms were not disclosed. Cosmos Health ( COSM ) previously entered the telehealth market in the US through its acquisition of Texas-based ZipDoctor.

Shares of Cosmos Health ( COSM ) recently were trading over 4% higher.

Price: 0.44, Change: +0.02, Percent Change: +4.83